Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC

NCT03331575 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT03331575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03331575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2017
Completion date
November 30, 2020
Enrollment
480 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable stage iii non-small-cell lung cancer